1373939-41-3

Upstream product

• 1373939-87-7 3-(3-bromo-4-methylphenyl)-5,5-dimethylisoxazol-4(5H)-one 
• 1373939-86-6 3-(3-bromo-4-methylphenyl)-5,5-dimethyl-4,5-dihydroisoxazol-4-ol 
• 1373939-85-5 (3-bromo-4-methylphenyl)(3,3-dimethyloxiran-2-yl)methanone 
• 1373938-01-2 N-(5-(5-(5,5-dimethyl-4-oxo-4,5-dihydroisoxazol-3-yl)-2-methylphenyl)pyrazin-2-yl)-2,6-difluorobenzamide 
• 1373939-84-4 1-(3-bromo-4-methylphenyl)-3-methylbut-2-en-1-one 
• 501420-55-9 3-bromo-N-methoxy-N,4-dimethylbenzamide 
• 1028700-78-8 N-(5-bromopyrazin-2-yl)-2,6-difluorobenzamide 
• 1373939-82-2 5,5-dimethyl-3-(4-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl) isoxazol-4(5H)-one 
• 7697-26-9 3-bromo-4-methylbenzoic acid 

Relevant academic research and scientific papers

OXAZOLE AND ISOXAZOLE CRAC MODULATORS

The present invention relates to compounds of Formula (I) along with processes for their preparation that are useful for treating, preventing and/or managing the diseases, disorders, syndromes or conditions associated with the modulation of CRAC. The invention further relates to methods of treating, preventing managing and/or lessening the diseases, disorders, syndromes or conditions associated with the modulation of CRAC of Formula (I).